Mikaela Dell'Oro

Ms. Mikaela Dell'Oro

Allied Health and Human Performance, University of South Australia, Adelaide, SA 5001, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MDMikaela Dell'Oro
Mikaela Dell'Oro
EGEileen Giles
Eileen Giles
ASAmy Sharkey
Amy Sharkey
MBMartin Borg
Martin Borg
CCCaroline Connell
Caroline Connell
EBEva Bezak
Eva Bezak
Background: Several studies have investigated cardiac dose reduction when utilizing the deep inspiration breath hold (DIBH) technique in patients undergoing radiotherapy for left-sided breast cancer. This paper aims to recommend potential selection criteria based on a retrospective single institute study of free breathing (FB) and DIBH computed tomography (CT) simulation planning scans. Methods: Dosimetric comparisons were performed retrospectively for 20 patients correlating the dose reduction and patient anatomical factors (anatomical variation of chest shape, chest wall separation, total lung volume (TLV) and others). Results: Paired t-tests demonstrated significant cardiac dose reduction for most patients but not all. Minimal cardiac dose reduction was observed for three patients using their DIBH plan, with one patient receiving a higher dose. Linear regression analysis identified a positive correlation between the patient’s TLV (on the FB CT simulation scan) and the magnitude of dosimetric benefit received (0.4045 R2). Conclusion: The TLV measured on a FB plan could potentially be utilised to predict cardiac exposure and assist with patient selection for DIBH. This is important in resource allocation, as DIBH may be unnecessarily recommended for some patients with little dosimetric benefit.

9 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MDMikaela Dell'Oro
Mikaela Dell'Oro
MSMichala Short
Michala Short
PWPuthenparampil A. Wilson
Puthenparampil A. Wilson
EBEva Bezak
Eva Bezak
Introduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. Methods: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE® database search in April 2019. Results: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. Conclusion: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.

10 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MDMikaela Dell'Oro
Mikaela Dell'Oro
MSMichala Short
Michala Short
PWPuthenparampil A. Wilson
Puthenparampil A. Wilson
CHChiaho Hua
Chiaho Hua
MGMelissa Gargone
Melissa Gargone
EBEva Bezak
Eva Bezak
Background: Proton radiotherapy produces superior dose distributions compared to photon radiotherapy, reducing side effects. Differences between the two modalities are not fully quantified in paediatric patients for various intracranial tumour sites or age. Understanding these differences may help clinicians estimate the benefit and improve referral across available centres. Our aim was to compare intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT) radiation doses for select paediatric intracranial tumours. Methods: IMPT and IMRT dose distributions for gender-matched paediatric cranial CT-datasets (ages 5, 9 and 13 years) were retrospectively calculated to simulate irradiation of supratentorial (ependymoma) and infratentorial (medulloblastoma) target volumes diameters (1–3 cm) and position (central and 1–2 cm shifts). Results: Clinical dosimetric objectives were achieved for all 216 treatment plans. Whilst infratentorial IMPT plans achieved greater maximum dose sparing to optic structures (4.8–12.6 Gy optic chiasm), brainstem sparing was limited (~0.5 Gy). Mean dose difference for optic chiasm was associated with medulloblastoma target position (p < 0.0197). Supratentorial IMPT plans demonstrated greater dose reduction for the youngest patients (pituitary gland p < 0.001). Conclusions: Normal tissue sparing was achieved regardless of patient age for infratentorial tumours. However, for supratentorial tumours, there was a dosimetric advantage of IMPT across 9 vs. 13-year-old patients.

Verified
Journal Article
Open access
PDF file
Loredana G MarcuLoredana G Marcu
Loredana G Marcu
MDMikaela Dell'Oro
Mikaela Dell'Oro
EBEva Bezak
Eva Bezak
Tumour repopulation during treatment is a well acknowledged yet still challenging aspect of cancer management. The latest research results show clear evidence towards the existence of cancer stem cells (CSCs) that are responsible for tumour repopulation, dissemination, and distant metastases in most solid cancers. Cancer stem cell quiescence and the loss of asymmetrical division are two powerful mechanisms behind repopulation. Another important aspect in the context of cancer stem cells is cell plasticity, which was shown to be triggered during fractionated radiotherapy, leading to cell dedifferentiation and thus reactivation of stem-like properties. Repopulation during treatment is not limited to radiotherapy, as there is clinical proof for repopulation mechanisms to be activated through other conventional treatment techniques, such as chemotherapy. The dynamic nature of stem-like cancer cells often elicits resistance to treatment by escaping drug-induced cell death. The aims of this scoping review are (1) to describe the main mechanisms used by cancer stem cells to initiate tumour repopulation during therapy; (2) to present clinical evidence for tumour repopulation during radio- and chemotherapy; (3) to illustrate current trends in the identification of CSCs using specific imaging techniques; and (4) to highlight novel technologies that show potential in the eradication of CSCs.

18 November 2021 in Medical Physics
Verified
Journal Article
Closed access
PDF file
MDMikaela Dell'Oro
Mikaela Dell'Oro
PWPuthenparampil Wilson
Puthenparampil Wilson
MSMichala Short
Michala Short
CHChia‐Ho Hua
Chia‐Ho Hua
TMThomas E. Merchant
Thomas E. Merchant
EBEva Bezak
Eva Bezak

1 August 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MDMikaela Dell'Oro
Mikaela Dell'Oro
MSMichala Short
Michala Short
PWPuthenparampil A. Wilson
Puthenparampil A. Wilson
EBEva Bezak
Eva Bezak